New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:16 EDTBCRFDA posts 12-month results of C.R. Bard Levant 2 trial
The FDA posted on its website briefing documents ahead of a circulatory system devices panel meeting scheduled for June 12, where an advisory committee will review C.R. Bard's Lutonix drug-coated balloon PTA catheter. Among the documents posted was C.R. Bard's executive summary, which contains the 12-month results of its pivotal Levant 2 trial. "Freedom from TLR was numerically favorable for the Lutonix DCB group, but no statistical difference between arms in Freedom from TLR rates was observed," the company stated in the summary. Reference Link
News For BCR From The Last 14 Days
Check below for free stories on BCR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
06:19 EDTBCRC.R. Bard management to meet with JMP Securities
Meeting to be held in Boston on September 23 hosted by JMP Securities.
September 15, 2014
07:45 EDTBCRCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use